Marianna Fontana, ESC 2022: The pathogenesis, prognosis and unmet needs in the treatment of transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic condition associated with progressive heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to discuss the pathogenesis, prognosis and the unmet needs in the treatment of ATTR-CM.
The abstract entitled ‘NNC60190001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTRCM): rationale and study design of a phase 2, randomized, placebo controlled trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- Could you give us a brief overview of transthyretin amyloid cardiomyopathy (ATTR-CM), its pathogenesis and prognosis? (0:24)
- What are unmet needs in the treatment of ATTR-CM? (2:02)
Disclosures: Marianna Fontana is on the advisory board and a consultant for Alexion, Alnylam, Caelum, Intellia, Ionis, Jannsen, Novo Nordisk and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!